Leerink Partners has reaffirmed its “Outperform” rating for Tenet Healthcare (THC) and increased its price target from $255.00 to $264.00, indicating a positive outlook for the company’s future growth. This is part of a trend of favorable analyst ratings and increased price targets from various firms such as Truist Securities, Guggenheim, Barclays, Keybanc, and UBS. While analysts project an average upside of 8.71% from the current price, GuruFocus estimates a potential downside of 37.11% based on its GF Value fair value assessment.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
THC: Leerink Partners Raises Price Target for Tenet Healthcare
Leerink Partners has reaffirmed its “Outperform” rating for Tenet Healthcare (THC) and increased its price target from $255.00 to $264.00, indicating a positive outlook for the company’s future growth. This is part of a trend of favorable analyst ratings and increased price targets from various firms such as Truist Securities, Guggenheim, Barclays, Keybanc, and UBS. While analysts project an average upside of 8.71% from the current price, GuruFocus estimates a potential downside of 37.11% based on its GF Value fair value assessment.